HUP0103651A3 - Paroxetine maleate and process for its preparation - Google Patents
Paroxetine maleate and process for its preparationInfo
- Publication number
- HUP0103651A3 HUP0103651A3 HU0103651A HUP0103651A HUP0103651A3 HU P0103651 A3 HUP0103651 A3 HU P0103651A3 HU 0103651 A HU0103651 A HU 0103651A HU P0103651 A HUP0103651 A HU P0103651A HU P0103651 A3 HUP0103651 A3 HU P0103651A3
- Authority
- HU
- Hungary
- Prior art keywords
- preparation
- paroxetine maleate
- paroxetine
- maleate
- Prior art date
Links
- AEIUZSKXSWGSRU-QXGDPHCHSA-N paroxetine maleate Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AEIUZSKXSWGSRU-QXGDPHCHSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/64—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9807627.6A GB9807627D0 (en) | 1998-04-09 | 1998-04-09 | Novel compounds |
| GBGB9823856.1A GB9823856D0 (en) | 1998-10-30 | 1998-10-30 | Novel compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0103651A2 HUP0103651A2 (en) | 2002-08-28 |
| HUP0103651A3 true HUP0103651A3 (en) | 2002-12-28 |
Family
ID=26313449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0103651A HUP0103651A3 (en) | 1998-04-09 | 1999-04-09 | Paroxetine maleate and process for its preparation |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1073652A1 (en) |
| JP (1) | JP2002511466A (en) |
| KR (1) | KR20010042552A (en) |
| CN (1) | CN1305474A (en) |
| AP (1) | AP2000001950A0 (en) |
| AU (1) | AU3433499A (en) |
| BG (1) | BG104914A (en) |
| BR (1) | BR9909529A (en) |
| CA (1) | CA2327450A1 (en) |
| EA (1) | EA200001050A1 (en) |
| HU (1) | HUP0103651A3 (en) |
| ID (1) | ID26879A (en) |
| IL (1) | IL138920A0 (en) |
| NO (1) | NO20005037L (en) |
| PL (1) | PL343378A1 (en) |
| SK (1) | SK15032000A3 (en) |
| TR (1) | TR200002939T2 (en) |
| WO (1) | WO1999052901A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6231833B1 (en) | 1999-08-05 | 2001-05-15 | Pfizer Inc | 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors |
| CH689805A8 (en) * | 1998-07-02 | 2000-02-29 | Smithkline Beecham Plc | Paroxetine methanesulfonate, process for its preparation and pharmaceutical compositions containing it. |
| GB9827387D0 (en) * | 1998-12-11 | 1999-02-03 | Smithkline Beecham Plc | Novel process |
| GB9827431D0 (en) * | 1998-12-11 | 1999-02-03 | Smithkline Beecham Plc | Novel compound |
| GB9914585D0 (en) * | 1999-06-22 | 1999-08-25 | Smithkline Beecham Plc | Novel process |
| NL1017421C2 (en) | 2001-02-21 | 2002-01-15 | Synthon Bv | Process for the production of paroxetine. |
| KR100672184B1 (en) | 2004-09-21 | 2007-01-19 | 주식회사종근당 | Paroxetine cholate or cholic acid derivative salts |
| ITTO20060143A1 (en) * | 2006-02-28 | 2007-09-01 | Bridgestone Corp | TIRE |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1422263A (en) * | 1973-01-30 | 1976-01-21 | Ferrosan As | 4-phenyl-piperidine compounds |
| AU3108097A (en) * | 1997-06-10 | 1998-12-30 | Synthon B.V. | 4-phenylpiperidine compounds |
-
1999
- 1999-04-09 EP EP99915911A patent/EP1073652A1/en not_active Ceased
- 1999-04-09 SK SK1503-2000A patent/SK15032000A3/en unknown
- 1999-04-09 PL PL99343378A patent/PL343378A1/en not_active Application Discontinuation
- 1999-04-09 BR BR9909529-7A patent/BR9909529A/en not_active Application Discontinuation
- 1999-04-09 JP JP2000543459A patent/JP2002511466A/en active Pending
- 1999-04-09 HU HU0103651A patent/HUP0103651A3/en unknown
- 1999-04-09 IL IL13892099A patent/IL138920A0/en unknown
- 1999-04-09 TR TR2000/02939T patent/TR200002939T2/en unknown
- 1999-04-09 ID IDW20002033A patent/ID26879A/en unknown
- 1999-04-09 KR KR1020007011214A patent/KR20010042552A/en not_active Application Discontinuation
- 1999-04-09 WO PCT/GB1999/001106 patent/WO1999052901A1/en not_active Application Discontinuation
- 1999-04-09 CN CN99807148A patent/CN1305474A/en active Pending
- 1999-04-09 AU AU34334/99A patent/AU3433499A/en not_active Abandoned
- 1999-04-09 EA EA200001050A patent/EA200001050A1/en unknown
- 1999-04-09 CA CA002327450A patent/CA2327450A1/en not_active Abandoned
- 1999-04-09 AP APAP/P/2000/001950A patent/AP2000001950A0/en unknown
-
2000
- 2000-10-06 NO NO20005037A patent/NO20005037L/en not_active Application Discontinuation
- 2000-11-07 BG BG104914A patent/BG104914A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TR200002939T2 (en) | 2001-02-21 |
| AP2000001950A0 (en) | 2000-12-31 |
| KR20010042552A (en) | 2001-05-25 |
| BG104914A (en) | 2001-10-31 |
| NO20005037L (en) | 2000-12-05 |
| SK15032000A3 (en) | 2001-04-09 |
| PL343378A1 (en) | 2001-08-13 |
| WO1999052901A1 (en) | 1999-10-21 |
| JP2002511466A (en) | 2002-04-16 |
| ID26879A (en) | 2001-02-15 |
| NO20005037D0 (en) | 2000-10-06 |
| AU3433499A (en) | 1999-11-01 |
| CA2327450A1 (en) | 1999-10-21 |
| HUP0103651A2 (en) | 2002-08-28 |
| CN1305474A (en) | 2001-07-25 |
| IL138920A0 (en) | 2001-11-25 |
| EA200001050A1 (en) | 2001-04-23 |
| BR9909529A (en) | 2000-12-12 |
| EP1073652A1 (en) | 2001-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GR3036208T3 (en) | Paroxetine methansulfonate | |
| HUP0004747A3 (en) | 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline derivatives and process for their preparation | |
| AP2000002010A0 (en) | Novel pharmaceutical compositions for treating and saving and the methods for the preparation thereof | |
| CZ20012118A3 (en) | Process for preparing 3-alkanoylindole and 3-alkylindole | |
| HUP0101779A3 (en) | Process for de-chlorinating and de-fouling waste-oil | |
| AU7334698A (en) | Process for preparing pure flupirtin maleate and its modification | |
| PL352432A1 (en) | Neurothrophic pyrolydines and piperidines, their affinite composition and methods of using them | |
| EP0990632A4 (en) | Adamantanemethanol derivatives and process for the preparation thereof | |
| AU1987400A (en) | Process for preparation of paroxetine maleate | |
| HUP0103651A2 (en) | Paroxetine maleate and process for its preparation | |
| HUP9902217A3 (en) | Polycation based bioconjugates and process for producing thereof | |
| HUP0101822A3 (en) | Effervescent compositions and process for their preparation | |
| HUP0202228A3 (en) | Low-dose tablets and preparation method | |
| HUP0101326A3 (en) | Paroxetine compositions and process for their preparation | |
| AU1291800A (en) | Microparticles and process for making microparticles | |
| GB9814869D0 (en) | Process and composition | |
| PL344872A1 (en) | Novel formulation containing paroxetine | |
| HUP0004503A3 (en) | Process for the preparation of paroxetine hydrochloride | |
| HUP0103569A3 (en) | New medicament and process for its preparation | |
| HUP0102116A3 (en) | Paroxetine ascorbate, process for its preparation and its pharmaceutical use | |
| HK1023559A1 (en) | Process for producing dichloroacetoxypropane and derivatives thereof | |
| HUP0101215A3 (en) | Chrystalline form of paroxetine | |
| AU6481799A (en) | Process for the preparation of paroxetine hydrochloride | |
| AU1396400A (en) | Process for the preparation of paroxetine hydrochloride | |
| HUP0101730A3 (en) | Method for preparing and using b-starch |